Donald E. Morel, Jr., Ph.D., was the CEO of West Pharmaceutical Services, Inc., where he made significant contributions to the company during his leadership from 2005 until his retirement in 2015. Holding a Ph.D. in pharmaceutical sciences, Morel leveraged his...

Donald E. Morel, Jr., Ph.D., was the CEO of West Pharmaceutical Services, Inc., where he made significant contributions to the company during his leadership from 2005 until his retirement in 2015. Holding a Ph.D. in pharmaceutical sciences, Morel leveraged his expertise to steer West Pharmaceutical towards innovation and growth in drug delivery systems. His leadership coincided with a substantial increase in the company's market value, evidenced by a remarkable spike in his insider trading activity, reaching up to $26.33 million in stock value by the end of 2021. During his tenure, he prioritized performance-based compensation to align the company's success with executive rewards. Before his retirement, he served both as CEO and Chairman, marking a significant period in the company's history. Notably, he retired in 2015 after announcing his intention to do so at the company's Annual Meeting, emphasizing a planned transition rather than an abrupt exit. Donald's strategic mindset and deep understanding of the industry led to impressive financial performance, with his compensation peaking at around $4.6 million in 2015. This combination of expertise and focus on shareholder value positioned West Pharmaceutical as a leader in its sector during his time.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other West Pharmaceutical Services CEOs

W

Donald E. Morel, Jr., Ph.D.

Ex-CEO of West Pharmaceutical Services

Education

Ph.D.

Sector of Economy

Healthcare

Born

June 1, 1951 - 73 years ago

CEO of West Pharmaceutical Services for

10 years 0 months (Jun 2005 - Jul 2015)

Previous Experience

Chairman and Chief Executive Officer

Rivals

Competitors/colleagues of Donald E. Morel, Jr., Ph.D.

C

Kevin J. McNamara

CEO of Chemed

2023 Compensation

Stock

$1.26M

Salary

$1.60M

Bonus

$2.92M

Other

$1.31M

Total Holdings

$62.25M

E

Mark J. Tarr

CEO of Encompass Health Corporation

2023 Compensation

Stock

$3.28M

Salary

$1.05M

Bonus

$0.00

Other

$66.92K

Total Holdings

$51.02M

Holdings

See how much did Donald E. Morel, Jr., Ph.D. make over time.

During his time as CEO of West Pharmaceutical Services, Donald E. Morel, Jr. saw his stock holdings escalate dramatically, reflecting both his confidence in the company and his significant insider trading activities. In 2019, his stock holdings were valued at...

During his time as CEO of West Pharmaceutical Services, Donald E. Morel, Jr. saw his stock holdings escalate dramatically, reflecting both his confidence in the company and his significant insider trading activities. In 2019, his stock holdings were valued at approximately $6.41 million, but this figure saw consistent growth, reaching as high as $26.33 million by September 2021. This trajectory underscores a period of robust performance at West Pharmaceutical as the market recognized the company's advancements in drug delivery systems. Notably, by the time of his retirement in 2015, Morel was firmly positioned with a vested interest in the success of West Pharmaceutical, further influencing his leadership decisions. His wealth in stock holdings fluctuated but showed a generally upward trend, showcasing his ability to capitalize on the company's growth.

Mar 18, 2025

W

shares

WST @ $234.47

Total Stock Sold

$5.87M

WST

$5.87M

140,000 WST shares

What if they kept their stock?

If Donald E. Morel, Jr., Ph.D. didn't sell their stock, today they would have:
Extra WST140,000 shares worth $22.81M.
This is 288.64% and $16.94M more than what they got when they sold the stock.

Charitable Transactions

WST

205,900 shares

WST

Recent Charitable Transactions

WST

15,000 shares

WST

Feb 26, 2015

Charity

WST

750 shares

WST

Feb 5, 2015

Charity

WST

9,300 shares

WST

Jan 12, 2015

Charity

WST

10,000 shares

WST

Dec 9, 2014

Charity

WST

5,000 shares

WST

Nov 12, 2014

Charity

WST

11,000 shares

WST

Sep 26, 2014

Charity

Insider Trading

See recent insider trades of Donald E. Morel, Jr., Ph.D..

WST

$1.09M

WST at $54.49/share

May 29, 2015

Sale

WST

$1.09M

WST at $54.29/share

May 14, 2015

Sale

WST

15,000 shares

WST

Feb 26, 2015

Charity

WST

$2.42M

WST at $51.53/share

Feb 17, 2015

Received

WST

750 shares

WST

Feb 5, 2015

Charity

WST

9,300 shares

WST

Jan 12, 2015

Charity

WST

$1.30K

WST at $54.67/share

Dec 19, 2014

Received

WST

10,000 shares

WST

Dec 9, 2014

Charity

WST

$1.30K

WST at $53.94/share

Dec 5, 2014

Received

WST

$1.30K

WST at $50.89/share

Nov 21, 2014

Received

Compensation History

See how much did Donald E. Morel, Jr., Ph.D. make over time.

Donald E. Morel, Jr.'s compensation as CEO of West Pharmaceutical peaked at about $4.6 million in 2015, encompassing a base salary, annual bonus, and additional benefits. In his last year, he earned a salary of $461,857 and a bonus of $537,413, highlighting the company's strong financial performance during his leadership. His compensation structure was mainly performance-based, designed to align the interests of the executives with that of the shareholders. Despite no stock awards vested in 2015 due to his retirement announcement, earlier years showed a trend of incentivizing performance through significant bonuses linked to achievement metrics like earnings per share and cash flow. The compensation philosophy at West emphasized attracting skilled management while ensuring that rewards were tied directly to the company's operational success.

Year

2015

Total Compensation

$1.97M

Salary

$461.86K

Board Justification

The compensation philosophy emphasizes alignment with shareholder interests and performance-based pay.

Bonus

$537.41K

Board Justification

Actual (above-target) bonus earned only for services as CEO and Chairman of the Board through June 30.

Other

$965.79K

Board Justification

Includes personal retirement benefits, payout of accrued vacation, and the transfer of his company vehicle.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock awards vested in 2015 as Dr. Morel's retirement was effective June 30, 2015.

Performance Metrics

Performance metrics for the AIP were based on adjusted diluted EPS and adjusted operating cash flow.

Other West Pharmaceutical Services CEOs

Here are other CEOs of West Pharmaceutical Services

Eric M. Green

CEO of West Pharmaceutical Services

April 2015 - Present